Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Date:8/12/2008

Medarex to Receive Milestone Payment from MedImmune

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.

The Phase 2A clinical trial is designed to evaluate the safety and tolerability of multiple subcutaneous dose schedules of MEDI-545 or placebo in adult patients with moderate to severe active lupus. The study will also assess the effects of MEDI-545 on disease activity in lupus patients. This randomized, double-blind, placebo-controlled trial is expected to enroll 80 patients and will be conducted at 20 sites in the United States.

MedImmune is also conducting a Phase 1 clinical trial for MEDI-545 in idiopathic inflammatory myositis, an immunological disease that involves chronic muscle inflammation, pain and weakness.

"Data from an earlier reported placebo-controlled Phase 1 study suggested therapeutic activity with single doses in patients with lupus and demonstrated an acceptable safety profile," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are very excited about the role of the interferon alpha inflammatory pathway and look forward to exploring its potential in treating patients with lupus and other autoimmune diseases."

About MEDI-545

MEDI-545 (previously known as MDX-1103) is a fully human monoclonal antibody targeting
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ -- Chindex International, ... American healthcare company providing services in ... Family Healthcare, a network of private hospitals and ... of its Beijing United Family Rehabilitation Hospital ("BJU ... of the United Family Healthcare ("UFH") network. On ...
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics ... from a human abuse liability (HAL) study for NKTR-181, ... of entry into the brain.  This slow rate of entry ... the abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and ...
(Date:6/19/2013)... June 19, 2013 Amerivet Solutions, LLC ... all branches of government from Federal to Municipal, ... their facilities to include complex metal design and ... some very complex aluminum parts for the Defense ... our capabilities to service government contracts," states ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... Sept. 16 The American,Chemistry Council is aware ... today in,the Journal of the American Medical Association ... concentrations and medical,disorders in adults. As with any ... design of a study can limit interpretation of ...
... Biotech Begins to Demonstrate Strategy to Expand NHL ... Preclinical Development Program -, BRITISH COLUMBIA, Canada, ... OTC Bulletin Board: IXSBF;, http://www.ixsbio.com ), a drug ... based on its technology, Dynamic Cross,Linking (DXL(TM)), announced ...
Cached Medicine Technology:New Bisphenol A Study Has Limited Capability to Assess Human Health Effects 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 3
(Date:6/19/2013)... Los Angeles, California (PRWEB) June 19, 2013 ... GoTunes for iPhone, a free music and fitness app ... GoTunes, you can discover new Spotify songs that match ... to when they exercise, and add songs to your ... albums, and songs curated by the GoTunes staff. , ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 Weight ... number of health care concerns including heart disease, kidney ... as the embarrassment of excess and unnecessary fat, have ... Doc created their hCG diets to not ... and weight maintenance, they also aim to reduce the ...
(Date:6/19/2013)... 19, 2013 After investing efforts for ... SizeItUp formally announced the launch of database integration ... is the latest entry in the list of extraordinary ... The completely redesigned 2012 Nissan NV is all ready ... critics alike. , Provided with two high power capable ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Audibel ... treatment solution for tinnitus patients, the A2 with ... for noise or ringing in the ears. Although ... serious within the body. , Using their patent-pending ... a customizable and comforting sound stimulus that resonates ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 According to ... drug abusers called “psychonauts” are creating new designer drugs ... their research of published documents and patented formulas. She ... Here & Now on June 4. , “Some ... effects. They’re never tested on humans. Maybe some of ...
Breaking Medicine News(10 mins):Health News:The GoTunes Iphone App Creates a Streaming Workout Music Community Via Spotify 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2Health News:Dangerous Designer Drugs Dodge Legal System 2Health News:Dangerous Designer Drugs Dodge Legal System 3
... injured during the earthquake require long-term specialized care to properly ... ... Beijing, China (Vocus) May 12, 2009 -- On the one-year ... Project HOPE , an international health education and humanitarian ...
... Health Organization urge vigilance against the "swine flu" (Type A influenza ... Huff, recommends practical tips for protecting your young child and baby ... ... Asheville, NC (PRWEB) May 12, 2009 -- The World Health Organization ...
... award-winning actress and Honorary Chairman of the,Avon Foundation ... survivors,and Avon Foundation for Women leaders for a ... the Avon Foundation Comprehensive Breast Center at the ... salute critical,partnerships that are making progress possible in ...
... Brookdale Senior Living Inc. (NYSE: BKD ) today ... Ohlendorf, Co-President and Chief Financial Officer, will make a presentation ... Lynch 2009 Health Care Conference in New York, NY on ... presentation is being audio webcast live and can be accessed ...
... Chemical Entity for Topical Acne Treatment in a DecadeCARLSBAD, Calif., ... has entered into a co-promotion agreement with Allergan for ... vulgaris. Representing the first new molecule in a decade approved ... patients 12 years of age and older, ACZONE(R) Gel 5% ...
... The following statement is from Regence BlueCross BlueShield President ... today,s announcement by a group of private-sector health industry leaders ... to save as much as $2 trillion over the next ... health care costs in our nation. We are a ...
Cached Medicine News:Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 2Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 3Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 2Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 3Health News:MultiVu Video Feed: REESE WITHERSPOON JOINS AVON FOUNDATION FOR WOMEN AND SAN FRANCISCO GENERAL HOSPITAL TO CELEBRATE 5TH ANNIVERSARY OF AVON COMPREHENSIVE BREAST CENTER 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 3Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 4Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2
... The electronic, motorized rotary ... all applications of paraffin, ... hard specimens in clinical, ... These instruments display extra-ordinary ...
... new face-lifted Leica RM2125 microtome comes in ... and Leica RM2125 RT. All RM2125 versions ... avoid debris entering the precision micrometer feeding ... a two-step trimming function and specimen retraction ...
... The Leica SM2500 large scale heavy-duty sectioning system ... large sectioning techniques a real working animal. ... and hard materials such as bone or teeth ... sectioned. The wide range of accessories, specially designed ...
... Designed for biomedical and industrial applications, the ... a variety of applications in all laboratories ... to be sectioned. Its sturdy construction lends ... The safety features of the system, such ...
Medicine Products: